Tuesday, 18 Jun 2019

You are here

RheumNow Podcast – Drug Ad Transparency (6.7.19)

Dr. Jack Cush reviews the news and journal articles of note from this past week on RheumNow.com.

  1. FDA sent an "untitled"letter to "R3 Stem Cell" for touting birth tissue products as Rx for ailments (without scientific evidence). FDA also won a case against "US Stem Cell clinics" for adulterated & misbranded stem cell products  https://buff.ly/2EU9uYN  https://buff.ly/2ZceqQr
  2. Transparency is coming? The Prices will soon be Included in TV Drug Ads. HHS Secretary Alex Azar has finalized regulations requiring drug companies to disclose list prices of medications costing more than $35 for a month’s supply. https://t.co/P2DPwXGYXK
  3. Korean Natl Claims Database examined RA & risk of opportunistic infx- OI, H zoster & candidiasis are seen in early RA. SIR for OI in early RA=1.14 (95% CI, 1.05‐1.23). H zoster (1.12), candidiasis (2.40); Age, steroids & comorbidity increased OI risk https://t.co/U7LPMpmPqG 
  4. CDC has updated its recommendations for TB testing of health care personnel. All HCP should be tested initially but after TB risk assessment, there is no need for routine or serial TB testing in the absence of exposure or ongoing risk of TB. https://t.co/qtAdz8d7OK 
  5. Metformin, was given to a mouse model Sjogrens (NOD)/ShiLtJ mice) & reduced salivary inflammation, IL-6,TNFα, IL-17 mRNA, improved salivary flow rate, suppressed effector T cells, inducec regulatory T cells & B cell diff. Why are mice so easy, SS so tough? https://t.co/yC5fJIBBEx
  6. UK Clinical Practice Database matched 62,234 pts with and without gout showing more venous thromboembolic events in gout (0.373 vs 0.27 per 100 Pt-yrs) (aHR 1.25, 95% CI 1.15–1.35) - not affected by ULT & not significant while in hospital (aHR 1.01) https://t.co/XrInEwckez
  7. Low Remission/LDA Rates with TNF inhibitors in Rheumatoid Arthritis   
  8. Proinflammatory Diets May Increase CRP and RA Onset 
  9. FDA Public Review of CBD Oil   
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

EULAR 2019- Day 4 Report

Saturday June 15th was the last half-day at EULAR 2019 but was highlighted by the “late-breaking” (LB) presentations that were presented from the podium and by poster.

Below are the top “LB” presentations from EULAR this year:

Understanding Non-arthritic Rheumatic iRAEs

A better understanding of rheumatic immune-related adverse event phenotypes beyond inflammatory arthritis has been furthered by work from three abstracts presented at EULAR 2019 in Madrid.

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.

EULAR 2019 – Day 3 Report

The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.

1. Genovese Vagal nerve stimulator in RA

2. Low dose steroids in Hand OA